Flamel
Technologies About
Flamel was a French alchemist in the Middle Ages... learn
more Flamel Technologies is a drug delivery company with expertise in polymer
chemistry. The company was founded in 1990 by Gerard Soula. In 1996, Flamel Technologies
(FLML) became the second French biotech company to enter the Nasdaq. The Company
has assembled a strong team of researchers expert in polymer science and biochemistry,
and owns a 50,000-square foot cGMP pharmaceutical production facility located
in Pessac, France (with an annual production capacity of 2 billion tablets or
capsules). Flamel’s drug delivery platforms, Medusa® for proteins and Micropump®
for small molecules , have been developed to improve the therapeutic characteristics,
safety profile and ease of use of wide variety of drugs drugs. The Company is
a recognized world leader in the innovation of delivery systems for small molecule
and protein drugs, providing tailored solutions to the biotech and pharmaceutical
industries for optimized controlled-release delivery of drugs. Flamel is turning
already-marketed or new drugs into more effective and safer medicines for itself
and for its partners. Since its inception, Flamel’s area of
expertise has been in polymer chemistry, though we are now recognized for our
cutting-edge work in drug delivery. It is an important field, both in terms of
the benefits such technology brings to patients and the economic opportunities
that result. As a relatively young company, a major challenge that we face is
to exploit simultaneously the many opportunities we have identified for the Medusa®
and Micropump® platforms. More
on Flamel Key
Statistics for Flamel Analyst
Opinion News
Basic
Chart for Flamel
Analysts
Estimates